Treatment of hepatoblastoma in the German cooperative pediatric liver tumor studies.
Treatment of hepatoblastoma in the German cooperative pediatric liver tumor studies.
复制标题
德国儿童肝脏肿瘤合作研究中肝母细胞瘤的治疗。
DOI：
10.2741/395
复制
发表时间：
2012
期刊：
影响因子：
--
通讯作者：
D. Schweinitz
中科院分区：
文献类型：
--
作者：
B. Haeberle;D. Schweinitz
新辅助化疗和辅助化疗联合肿瘤切除改变了肝母细胞瘤的治疗策略，并导致了前瞻性合作研究。本文综述了德国三项肝肿瘤研究HB89、HB94和HB99的治疗策略和结果。在这里，我们提供了一个概述的治疗这种肿瘤在1989年至2008年在德国。概述了治疗方案、研究目的和结果。观察不同治疗方案的总生存期、化疗反应及毒副反应。在过去几年中，总体生存率有所改善，HB 89为75%，HB 94为77%，HB 99为89%。具有潜在可切除肿瘤的患者具有良好的预后，尽管在过去几年中治疗减少。不可切除的肿瘤或肺转移的患者也有较好的预后，但仍然很差。过去几年在德国对这些患者的强化治疗显示出与国际研究相当的结果，但没有优势。
Treatment with neoadjuvant and adjuvant chemotherapy together with tumor resection changed treatment strategies in hepatoblastoma and led to prospective cooperative studies. The treatment strategies and results of three German liver tumor studies HB89, HB94 and HB99 are reviewed. Here we provide an overview of the treatment of this tumor in the years 1989 to 2008 in Germany. The treatment protocols, aim of studies and results are outlined. The overall-survival (OS), response to chemotherapy and toxicity are followed over this period of different treatment. The overall-survival improved over the last years with 75 % in HB89, 77 % in HB94 and 89 % HB99. Patients with potentially resectable tumors have a good prognosis although the treatment was reduced over the last years. Patients with non resectable tumors or lung metastases have also a better but still bad prognosis. The intensified treatment for these patients in Germany in the last years showed comparable results to international studies but no advantage.